NVCR News and Press, NovoCure Limited From 09/09/21

NovoTTF-200T is a Tumor Treating Fields delivery system intended for use together with atezolizumab and bevacizumab for the treatment of patients with advanced liver cancer Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has grant...

Novocure (NASDAQ: NVCR) announced today that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021. Ms. Cordova and Mr. Shah will take part in a fireside chat at 1...

Novocure (NASDAQ: NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of Novocure’s team members to our anticipated growth. Mr. Burke joined Novocure in 2014 ...

On Aug. 16, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q2 2021. I curated a list of some of the best-performing hedge funds and looked into their holdings at the end of June 2021. Several common themes appear whe...

Novocure (NASDAQ: NVCR) disappointed investors with its second-quarter results announced on July 29. However, the company could have better news on the way. In this Motley Fool Live video recorded on Aug. 4 , Motley Fool contributors Keith Speights and Brian Orelli discuss w...

Shares of Novocure (NASDAQ: NVCR) slid this week in response to a disappointing second-quarter earnings report. Investors aren't happy about the slower-than-anticipated rollout of the company's Tumor Treating Fields, or TTF, therapy. The healthcare stock finished the week down 18.7%...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q2 earnings call. For further details see: NovoCure Limited 2021 Q2 - Results - Earnings Call Presentation

Quarterly earnings aren't providing much of a cure for Novocure (NASDAQ: NVCR) . The company, which concentrates on novel cancer-fighting solutions, saw its stock dive by almost 10% on Thursday following the publication of its latest set of results. In Q2, Novocure took in $...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2021 Earnings Call Jul 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2021 Earnings Call Transcript

NovoCure Limited (NVCR) Q2 2021 Earnings Conference Call July 29, 2021 08:00 AM ET Company Participants Ingrid Goldberg - Vice President Finance & Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Uri Weinbe...